Lymph node metastases and recurrence in pT1 colorectal cancer: Prediction with the International Budding Consortium Score—A retrospective, multi-centric study
Dawson H, Bokhorst JM, Studer L, Vieth M, Oguz Erdogan AS, Kus Öztürk S, Kirsch R, Brockmoeller S, Cathomas G, Buslei R, Fink D, Roumet M, Zlobec I, van der Laak J, Nagtegaal ID, Lugli A (2024)
Publication Language: English
Publication Type: Journal article, Original article
Publication year: 2024
Journal
DOI: 10.1002/ueg2.12521
Abstract
Background: The International Collaboration on Cancer Reporting proposes histological tumour type, lymphovascular invasion, tumour grade, perineural invasion, extent, and dimensions of invasion as risk factors for lymph node metastases and tumour progression in completely endoscopically resected pT1 colorectal cancer (CRC). Objective: The aim of the study was to propose a predictive and reliable score to optimise the clinical management of endoscopically resected pT1 CRC patients. Methods: This multi-centric, retrospective International Budding Consortium (IBC) study included an international pT1 CRC cohort of 565 patients. All cases were reviewed by eight expert gastrointestinal pathologists. All risk factors were reported according to international guidelines. Tumour budding and immune response (CD8+ T-cells) were assessed with automated models using artificial intelligence. We used the information on risk factors and least absolute shrinkage and selection operator logistic regression to develop a prediction model and generate a score to predict the occurrence of lymph node metastasis or cancer recurrence. Results: The IBC prediction score included the following parameters: lymphovascular invasion, tumour buds, infiltration depth and tumour grade. The score has an acceptable discrimination power (area under the curve of 0.68 [95% confidence intervals (CI) 0.61–0.75]; 0.64 [95% CI 0.57–0.71] after internal validation). At a cut-off of 6.8 points to discriminate high-and low-risk patients, the score had a sensitivity and specificity of 0.9 [95% CI 0.8–0.95] and 0.26 [95% 0.22, 0.3], respectively. Conclusion: The IBC score is based on well-established risk factors and is a promising tool with clinical utility to support the management of pT1 CRC patients.
Authors with CRIS profile
Involved external institutions
Universität Bern
Switzerland (CH)
Radboud University Nijmegen Medical Centre / Radboudumc of voluit Radboud Universitair Medisch Centrum (UMC)
Netherlands (NL)
University of Toronto
Canada (CA)
University of Leeds
United Kingdom (GB)
Kantonsspital Baselland
Switzerland (CH)
Sozialstiftung Bamberg
Germany (DE)
Baylor College of Medicine
United States (USA) (US)
Switzerland (CH)
Radboud University Nijmegen Medical Centre / Radboudumc of voluit Radboud Universitair Medisch Centrum (UMC)
Netherlands (NL)
University of Toronto
Canada (CA)
University of Leeds
United Kingdom (GB)
Kantonsspital Baselland
Switzerland (CH)
Sozialstiftung Bamberg
Germany (DE)
Baylor College of Medicine
United States (USA) (US)
How to cite
APA:
Dawson, H., Bokhorst, J.M., Studer, L., Vieth, M., Oguz Erdogan, A.S., Kus Öztürk, S.,... Lugli, A. (2024). Lymph node metastases and recurrence in pT1 colorectal cancer: Prediction with the International Budding Consortium Score—A retrospective, multi-centric study. United European Gastroenterology Journal. https://dx.doi.org/10.1002/ueg2.12521
MLA:
Dawson, Heather, et al. "Lymph node metastases and recurrence in pT1 colorectal cancer: Prediction with the International Budding Consortium Score—A retrospective, multi-centric study." United European Gastroenterology Journal (2024).
BibTeX: Download